Literature DB >> 15914065

Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis.

Vasan K Sambandamurthy1, William R Jacobs.   

Abstract

The recent advances in genetic tools to manipulate Mycobacterium tuberculosis have led to the construction of defined mutants and to the study of their role in the virulence and pathogenesis of tuberculosis. The safety and vaccine potential of a few of these M. tuberculosis mutants as candidate vaccines against tuberculosis are discussed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15914065     DOI： 10.1016/j.micinf.2005.04.001

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  22 in total

1.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

2.  Combined Bioinformatic and Rational Design Approach To Develop Antimicrobial Peptides against Mycobacterium tuberculosis.

Authors:  C Seth Pearson; Zachary Kloos; Brian Murray; Ebot Tabe; Monica Gupta; Jun Ha Kwak; Pankaj Karande; Kathleen A McDonough; Georges Belfort
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 3.  Mycobacterium tuberculosis in the Face of Host-Imposed Nutrient Limitation.

Authors:  Michael Berney; Linda Berney-Meyer
Journal:  Microbiol Spectr       Date:  2017-06

4.  Rapid Whole-Cell Assay of Antitubercular Drugs Using Second-Generation Fluoromycobacteriophages.

Authors:  Estefanía Urdániz; Liliana Rondón; Marcelo A Martí; Graham F Hatfull; Mariana Piuri
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Protection elicited by two glutamine auxotrophs of Mycobacterium tuberculosis and in vivo growth phenotypes of the four unique glutamine synthetase mutants in a murine model.

Authors:  Sunhee Lee; Bo-Young Jeon; Svetoslav Bardarov; Mei Chen; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2006-11       Impact factor: 3.441

Review 6.  Vaccine development for tuberculosis: current progress.

Authors:  Ian M Orme
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

7.  IL17A augments autophagy in Mycobacterium tuberculosis-infected monocytes from patients with active tuberculosis in association with the severity of the disease.

Authors:  Nancy Liliana Tateosian; Joaquín Miguel Pellegrini; Nicolás Oscar Amiano; Agustín Rolandelli; Nicolás Casco; Domingo Juan Palmero; María Isabel Colombo; Verónica Edith García
Journal:  Autophagy       Date:  2017-06-05       Impact factor: 16.016

8.  Safety and immunogenicity of the Mycobacterium tuberculosis DeltalysA DeltapanCD vaccine in domestic cats infected with feline immunodeficiency virus.

Authors:  Dawn M Zimmerman; W Ray Waters; Konstantin P Lyashchenko; Brian J Nonnecke; Douglas L Armstrong; William R Jacobs; Michelle H Larsen; Erin Egan; Gregg A Dean
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

9.  Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis.

Authors:  Joseph Hinchey; Bo Y Jeon; Holly Alley; Bing Chen; Michael Goldberg; Steven Derrick; Sheldon Morris; William R Jacobs; Steven A Porcelli; Sunhee Lee
Journal:  PLoS One       Date:  2011-01-10       Impact factor: 3.240

10.  Efficacy and immunogenicity of Mycobacterium bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves.

Authors:  W Ray Waters; Mitchell V Palmer; Brian J Nonnecke; Tyler C Thacker; Charles F Capinos Scherer; D Mark Estes; R Glyn Hewinson; H Martin Vordermeier; S Whitney Barnes; Glenn C Federe; John R Walker; Richard J Glynne; Tsungda Hsu; Brian Weinrick; Karolin Biermann; Michelle H Larsen; William R Jacobs
Journal:  Vaccine       Date:  2009-01-09       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.